For example, drugs such as the EGFR antibody, Cetuximab© or the tyrosine kinase inhibitors, Gefitinib© and Erlotinib©, target EGFR and are often used in SCCHN therapy (6). Here, EGFR is linked to head and neck squamous cell carcinoma.